Trustmark Bank Trust Department Sells 32,341 Shares of Bristol Myers Squibb Company $BMY

Trustmark Bank Trust Department reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 41.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,425 shares of the biopharmaceutical company’s stock after selling 32,341 shares during the quarter. Trustmark Bank Trust Department’s holdings in Bristol Myers Squibb were worth $2,149,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Bristol Myers Squibb by 3.4% in the first quarter. Harbour Investments Inc. now owns 30,284 shares of the biopharmaceutical company’s stock valued at $1,847,000 after buying an additional 982 shares during the period. Alberta Investment Management Corp acquired a new stake in Bristol Myers Squibb during the first quarter worth approximately $10,874,000. Certified Advisory Corp increased its stake in Bristol Myers Squibb by 7.5% during the 1st quarter. Certified Advisory Corp now owns 4,243 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 297 shares during the period. Finally, MONECO Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 2.6% during the 1st quarter. MONECO Advisors LLC now owns 17,254 shares of the biopharmaceutical company’s stock worth $1,052,000 after purchasing an additional 431 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of several analyst reports. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Scotiabank began coverage on Bristol Myers Squibb in a research report on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price objective for the company. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $54.42.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $49.18 on Friday. The firm has a market capitalization of $100.11 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The business’s 50-day moving average price is $45.59 and its 200-day moving average price is $46.63. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same period last year, the company earned $1.80 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.0%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.